Cargando…

After 25 years of drug development, do we know JAK?

Detalles Bibliográficos
Autores principales:	Mortezavi, Mahta, Martin, David A, Schulze-Koops, Hendrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280879/ https://www.ncbi.nlm.nih.gov/pubmed/35831034 http://dx.doi.org/10.1136/rmdopen-2022-002409

Ejemplares similares

Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort
por: Mueller, Ruediger B, et al.
Publicado: (2018)

Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
por: Matucci-Cerinic, Marco, et al.
Publicado: (2018)

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
por: Kay, Jonathan, et al.
Publicado: (2020)

Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial
por: Balanescu, Andra-Rodica, et al.
Publicado: (2022)

JAK inhibition and the holy grail for pain control in early RA
por: Pazmino, Sofia, et al.
Publicado: (2022)

Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
por: Molander, Viktor, et al.
Publicado: (2023)

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
por: Lauper, Kim, et al.
Publicado: (2022)

Biosimilars in rheumatology: what the clinician should know
por: Castañeda-Hernández, Gilberto, et al.
Publicado: (2015)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
por: Traves, Paqui G, et al.
Publicado: (2021)

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers
por: Chatzidionysiou, Katerina, et al.
Publicado: (2020)

Being as Normal as Possible: How Young People Ages 16–25 Years Evaluate the Risks and Benefits of Treatment for Inflammatory Arthritis
por: Hart, Ruth I., et al.
Publicado: (2016)

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
por: Vanhoutte, Frédéric, et al.
Publicado: (2017)

Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
por: Genovese, Mark C., et al.
Publicado: (2016)

Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
por: Robinson, Michael F., et al.
Publicado: (2020)

Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis
por: Kjelgaard‐Petersen, Cecilie F., et al.
Publicado: (2018)

A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy
por: Kremer, Joel M., et al.
Publicado: (2016)

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
por: Bergstra, Sytske Anne, et al.
Publicado: (2020)

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: van der Heijde, Desirée, et al.
Publicado: (2018)

Risk factors for venous thromboembolism and atherosclerotic cardiovascular disease: do they differ in patients with rheumatoid arthritis?
por: Ozen, Gulsen, et al.
Publicado: (2021)

How do multiple long-term conditions impact on the cost-of-illness in early rheumatoid arthritis?
por: Hsieh, Ping-Hsuan, et al.
Publicado: (2022)

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
por: Cohen, Stanley B, et al.
Publicado: (2020)

‘Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?’
por: Goodman, Susan M, et al.
Publicado: (2020)

Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients
por: Gossec, Laure, et al.
Publicado: (2019)

What do patients prefer? A multinational, longitudinal, qualitative study on patient-preferred treatment outcomes in early rheumatoid arthritis
por: Van der Elst, Kristien, et al.
Publicado: (2020)

Serum calprotectin levels do not predict subsequent relapse in rheumatoid arthritis in remission: a post-hoc analysis of STRASS study
por: Romand, Xavier, et al.
Publicado: (2023)

Glucocorticoid trajectories over 2 years in patients with rheumatoid arthritis in a real-life setting
por: Delteil, Alycia, et al.
Publicado: (2023)

Possibilities for personalised medicine in rheumatoid arthritis: hype or hope
por: Heutz, Judith, et al.
Publicado: (2021)

Phenotypic, Functional, and Gene Expression Profiling of Peripheral CD45RA+ and CD45RO+ CD4+CD25+CD127(low) Treg Cells in Patients With Chronic Rheumatoid Arthritis
por: Walter, Gina J., et al.
Publicado: (2015)

One in five patients with rapidly and persistently controlled early rheumatoid arthritis report poor well-being after 1 year of treatment
por: Van der Elst, Kristien, et al.
Publicado: (2020)

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Infliximab Versus Conventional Combination Treatment and Seven‐Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial
por: Eriksson, Jonas K., et al.
Publicado: (2016)

Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2023)

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study
por: Emery, Paul, et al.
Publicado: (2019)

Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trial
por: van der Pol, Joy Ardjuna, et al.
Publicado: (2023)

Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study
por: Alten, Rieke, et al.
Publicado: (2016)

Peptidylarginine Deiminase Autoimmunity and the Development of Anti–Citrullinated Protein Antibody in Rheumatoid Arthritis: The Hapten–Carrier Model
por: Auger, Isabelle, et al.
Publicado: (2020)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure
por: Rivellese, F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bts9j8nlr4c7f7vk51bgt8tc0q